CO2022014499A2 - Moduladores de nlrp3 - Google Patents
Moduladores de nlrp3Info
- Publication number
- CO2022014499A2 CO2022014499A2 CONC2022/0014499A CO2022014499A CO2022014499A2 CO 2022014499 A2 CO2022014499 A2 CO 2022014499A2 CO 2022014499 A CO2022014499 A CO 2022014499A CO 2022014499 A2 CO2022014499 A2 CO 2022014499A2
- Authority
- CO
- Colombia
- Prior art keywords
- nlrp3 modulators
- nlrp3
- modulators
- disorders
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Burglar Alarm Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990363P | 2020-03-16 | 2020-03-16 | |
| PCT/US2021/022397 WO2021188450A1 (en) | 2020-03-16 | 2021-03-15 | Nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014499A2 true CO2022014499A2 (es) | 2023-02-16 |
Family
ID=77747550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014499A CO2022014499A2 (es) | 2020-03-16 | 2022-10-12 | Moduladores de nlrp3 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11603375B2 (https=) |
| EP (1) | EP4121059A4 (https=) |
| JP (2) | JP2023518044A (https=) |
| KR (1) | KR20220154165A (https=) |
| CN (1) | CN115605209B (https=) |
| AR (1) | AR121573A1 (https=) |
| AU (1) | AU2021237477A1 (https=) |
| BR (1) | BR112022018480A2 (https=) |
| CA (1) | CA3175729A1 (https=) |
| CL (1) | CL2022002531A1 (https=) |
| CO (1) | CO2022014499A2 (https=) |
| IL (1) | IL296488A (https=) |
| MX (1) | MX2022011576A (https=) |
| PH (1) | PH12022552447A1 (https=) |
| TW (1) | TWI901652B (https=) |
| WO (1) | WO2021188450A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| JP7595642B2 (ja) | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| KR20220154165A (ko) | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| WO2025255532A1 (en) * | 2024-06-07 | 2025-12-11 | Zomagen Biosciences Ltd | Combination therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2119705A1 (en) * | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| KR20110073500A (ko) * | 2008-09-08 | 2011-06-29 | 메르크 파텐트 게엠베하 | 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘 |
| CN107207431B (zh) * | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
| KR102727059B1 (ko) | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| CN109071454B (zh) | 2016-02-16 | 2023-02-17 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| US11597706B2 (en) * | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| JP2020531448A (ja) * | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| WO2019166624A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN113056451A (zh) | 2018-10-24 | 2021-06-29 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| JP7595642B2 (ja) | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| KR20220154165A (ko) | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | Nlrp3 조절제 |
-
2021
- 2021-03-15 KR KR1020227035334A patent/KR20220154165A/ko active Pending
- 2021-03-15 BR BR112022018480A patent/BR112022018480A2/pt not_active Application Discontinuation
- 2021-03-15 WO PCT/US2021/022397 patent/WO2021188450A1/en not_active Ceased
- 2021-03-15 EP EP21770604.3A patent/EP4121059A4/en active Pending
- 2021-03-15 IL IL296488A patent/IL296488A/en unknown
- 2021-03-15 PH PH1/2022/552447A patent/PH12022552447A1/en unknown
- 2021-03-15 AU AU2021237477A patent/AU2021237477A1/en active Pending
- 2021-03-15 AR ARP210100650A patent/AR121573A1/es unknown
- 2021-03-15 CN CN202180035570.2A patent/CN115605209B/zh active Active
- 2021-03-15 MX MX2022011576A patent/MX2022011576A/es unknown
- 2021-03-15 US US17/202,047 patent/US11603375B2/en active Active
- 2021-03-15 JP JP2022555714A patent/JP2023518044A/ja not_active Ceased
- 2021-03-15 CA CA3175729A patent/CA3175729A1/en active Pending
- 2021-03-16 TW TW110109276A patent/TWI901652B/zh active
-
2022
- 2022-09-15 CL CL2022002531A patent/CL2022002531A1/es unknown
- 2022-10-12 CO CONC2022/0014499A patent/CO2022014499A2/es unknown
-
2023
- 2023-02-02 US US18/163,680 patent/US20230183258A1/en not_active Abandoned
- 2023-10-09 US US18/483,397 patent/US20240101571A1/en not_active Abandoned
-
2025
- 2025-03-04 JP JP2025033957A patent/JP2025102771A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220154165A (ko) | 2022-11-21 |
| CL2022002531A1 (es) | 2023-03-31 |
| US11603375B2 (en) | 2023-03-14 |
| TWI901652B (zh) | 2025-10-21 |
| EP4121059A1 (en) | 2023-01-25 |
| TW202200584A (zh) | 2022-01-01 |
| US20230183258A1 (en) | 2023-06-15 |
| WO2021188450A1 (en) | 2021-09-23 |
| BR112022018480A2 (pt) | 2022-11-29 |
| AR121573A1 (es) | 2022-06-15 |
| AU2021237477A1 (en) | 2022-10-13 |
| JP2025102771A (ja) | 2025-07-08 |
| PH12022552447A1 (en) | 2024-01-03 |
| US20240101571A1 (en) | 2024-03-28 |
| JP2023518044A (ja) | 2023-04-27 |
| CA3175729A1 (en) | 2021-09-23 |
| IL296488A (en) | 2022-11-01 |
| MX2022011576A (es) | 2022-10-18 |
| US20210292336A1 (en) | 2021-09-23 |
| CN115605209A (zh) | 2023-01-13 |
| EP4121059A4 (en) | 2023-12-13 |
| CN115605209B (zh) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002767A1 (es) | Moduladores de nlrp3 | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| UY40021A (es) | Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| JOP20230190A1 (ar) | مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CO2026004964A2 (es) | Moduladores de kras | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| UY38186A (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| MX2024012801A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| MX2021008941A (es) | Moduladores gpr35. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
| MX2022009762A (es) | Moduladores del purinorreceptor 3 p2x (p2x3). | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| EP4553065A3 (en) | Novel compounds for treating mitochondrial disease | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas |